Bepirovirsen cures 19% of chronic hepatitis B patients in phase 3 trials
Two phase 3 trials enrolling more than 1,800 patients have shown that bepirovirsen, a GSK antisense oligonucleotide, achieves a functional cure in roughly one in five people with chronic hepatitis B — the first drug to do so without requiring lifelong daily treatment.
Pooled across two trials: 233 of 1,220 treated patients reached functional cure after 24 weeks of bepirovirsen versus zero of 614 on placebo (p<0.001), published simultaneously in NEJM.
The catch a commenter flagged: trials enrolled non-cirrhotic patients with moderate antigen loads already on stable therapy — the group least likely to die. Most of HBV's 1.1M annual deaths are cirrhotic patients, excluded here.
FDA granted breakthrough designation and priority review, decisions expected Q3 2026 — whether 19% holds in harder cases is unknown.
The First Drug to Clear Hepatitis B Surface Antigen at Scale
For decades, chronic hepatitis B has been manageable but not curable. Nucleotide analogues (tenofovir, entecavir) suppress viral replication but must be taken indefinitely; functional cure — defined as sustained clearance of hepatitis B surface antigen (HBsAg) — happens spontaneously in fewer than 1% of patients per year on those drugs. A new Science.org report covers results that change that baseline dramatically.
What Bepirovirsen Does and What the Trials Found
Bepirovirsen is an antisense oligonucleotide developed by GSK and Ionis Pharmaceuticals. It targets and degrades HBV RNA, reducing both viral replication and the surface antigen that allows the virus to evade immune clearance. Unlike nucleotide analogues, it is given as a subcutaneous injection over a finite 24-week course.
The B-Well 1 and B-Well 2 phase 3 trials enrolled 1,834 patients total — non-cirrhotic adults with chronic HBV who were already on stable nucleotide analogue therapy and had baseline HBsAg levels between 100 and 3,000 IU/mL. Pooled results, published simultaneously in the New England Journal of Medicine and presented at the EASL congress:
| Outcome | Bepirovirsen (n=1,220) | Placebo (n=614) |
|---|---|---|
| Functional cure (HBsAg loss + undetectable HBV DNA) | 19% (233 patients) | 0% |
| Statistical significance | p<0.001 (both trials) | — |
FDA has granted bepirovirsen breakthrough therapy designation and priority review. GSK anticipates first regulatory decisions in Q3 2026.
The Thread's Key Caveat
The HN thread was thin, but one medically informed commenter identified the gap between the headline and the public-health reality in the thread:
"The trial enrolled non-cirrhotic patients with moderate baseline HBsAg (100 to 3,000 IU/mL) already on stable nucleotide analogue therapy. That selection matters because HBV-related deaths are driven almost entirely by cirrhosis and hepatocellular carcinoma, and those outcomes cluster in patients with higher antigen loads and advanced disease. The 19% result is real and independently replicated in over 1,800 patients, but whether bepirovirsen reduces the 1.1 million HBV deaths per year depends on trials in populations that weren't enrolled here." — AI engineer and trial analyst
Another commenter raised an unresolved transmission question:
"Are treated patients still contagious? If so, if a treated patient spreads the virus, will that new patient carry an inoculated virus? Or will they suffer a standard infection?" — backend developer in Argentina
The source does not address post-cure transmissibility, which matters for vaccine-adjacent public health planning.
What Changes and What Doesn't Yet
A 19% functional cure rate, replicated across 1,800 patients in two blinded trials, is a genuine discontinuity from anything previously available. Hepatitis B infects an estimated 296 million people worldwide; fewer than 1% currently achieve HBsAg clearance annually on standard therapy. But the population that stands to benefit most — cirrhotic patients, those with high antigen loads, people in sub-Saharan Africa and Southeast Asia where HBV burden is highest — was systematically excluded from B-Well. The 19% is real. Whether it translates to reduced mortality at population scale requires trials that have not yet started.
Get breakdowns like this every day
The top Hacker News stories, unpacked — by email, Telegram, or RSS.
A 25-Year-Old Game Passes the Same AI Consciousness Tests LLMs Do
Researchers built a neural network inside Age of Empires II and used it to argue that every anthropomorphic claim made about large language models applies equally to medieval virtual peasants farming grain. The paper's punch line: if substrate doesn't matter, neither does the silicon.